This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Tetrahydroacridinamine

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Tacrine is not licenced in the UK but has been used in the US for the treatment of cognitive deficits of Alzheimer's disease. Its use is limited by a significant incidence of hepatotoxicity and mild cognitive benefits. It has been stated that tacrine does not alter the course of the disease (1).

Tacrine is a centrally active non-competitive reversible acetylcholinesterase inhibitor. The rationale for using a drug such as tacrine is that neurones that release acetylcholine are especially affected in Alzheimer's. There is correlation between the degree of cholinergic involvement and neuropathological variables such as plaque count and with the degree of dementia.

Tacrine is no longer prescribed due to a relatively unfavorable administration schedule (4 times daily) and side-effect profile (potential hepatotoxicity) (2).

Reference:

  • Davis KP, Powchik P.Tacrine, Lancet 1995;345:625-30.
  • Cognex . Atlanta, GA: Sciele Pharma Inc; 2008

Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.